Cogent Biosciences

Cellular immunotherapies

Also 2 trials Clin2 systemic mastocytosis; 6 undisclosed programs RD undisclosed

Cogent Biosciences is developing treatments for genetic diseases. Genetic mutations underpin and drive many diseases and require rational precision therapies to cure. Cogent is using established and emerging science to guide drug discovery and pioneer best-in-class therapeutics. Cogent’s most advanced program is Bezuclastinib, a potent and selective inhibitor of the protein Kit, a receptor tyrosine kinase. Kit is commonly mutated in gastrointestinal stromal tumors (GIST), and GIST patients often relapse with current therapeutics. Cogent hopes Bezuclastinib will offer a better clinical profile as it has already shown promising early clinical activity and safety. Cogent also has FGFR inhibitors in preclinical development for oncology.